Coordinating Global Drug and Diagnostic Submissions: A Harmonized Strategy

Introduction: The Need for Global Co-Submission Strategies

As personalized medicine becomes mainstream, companion diagnostics (CDx) play a critical role in selecting the right therapy for the right patient. However, regulatory authorities across the globe have distinct timelines, technical requirements, and processes for approving a drug and its associated diagnostic. These differences can hinder the simultaneous global launch of precision therapies.

This tutorial outlines the harmonization challenges in drug-CDx co-submission, explores country-specific regulatory landscapes, and offers practical strategies for global alignment, especially across the US (FDA), EU (EMA), Japan (PMDA), and other key markets.

FDA: Co-Development and Labeling Requirements

The US FDA expects the therapeutic and diagnostic components to be reviewed in parallel, culminating in simultaneous approval. Key expectations include:

• CDx Approval Pathway: Premarket Approval (PMA)
• Co-Labeling: CDx must be listed in the drug label and vice versa
• Guidance Documents: FDA Guidance on In Vitro Companion Diagnostic Devices (2014, 2020 update)
• Pre-Submission: Type C meetings or Q-submissions are highly recommended

CDx data must be generated and validated during the clinical development of the therapeutic product, with clearly defined endpoints and patient stratification based on biomarker status.

EMA: Consultation-Based Approval with Notified Body Involvement

In the EU, CDx are classified as Class C under the In Vitro Diagnostic Regulation (IVDR). Approval requires coordinated review by a Notified Body and the European Medicines Agency (EMA):

• Article 48(3): Requires Notified Body consultation with EMA for CDx
• Parallel Scientific Advice (PSA): Available for aligning CDx and drug development
• Labeling: Mutual reference between drug SmPC and CDx IFU required
• Submission: Requires separate but synchronized technical files

See harmonization strategies at EMA’s medical device portal.

PMDA (Japan): Bridging and Co-Approval Models

Japan’s PMDA and MHLW facilitate CDx and drug co-approvals through structured regulatory pathways, though independent submission tracks are still used:

• Pre-Submission Consultations: Multiple rounds of engagement required
• Bridging Studies: Critical when using foreign clinical trial data
• Labeling Coordination: Synchronized labeling with the companion therapeutic
• Timing: Submissions for both products should be aligned within a 3-month window

Many CDx in Japan are approved via partial change applications (PCA) when extending intended use for existing IVDs.

Key Challenges in Global Co-Submissions

Despite shared objectives, co-submission remains complex due to:

• Asynchronous approval timelines between regions
• Variability in biomarker validation standards (e.g., LOD, LOQ, PPA/NPA)
• Differing regulatory documentation formats
• Limited mutual recognition between FDA, EMA, PMDA

Example: A CDx for ALK mutations may be approved by FDA with 97% concordance, while EMA might request additional bridging data for CE marking under IVDR.

Sample Validation Values for Global Dossiers

Adopt global standards outlined in PharmaSOP.in.

Global Dossier Alignment: Technical File Synchronization

To achieve harmonization, developers must ensure that the diagnostic dossier (Design Dossier or STED) matches across submissions:

• Content Modules: Analytical, clinical, manufacturing, labeling
• Regulatory Templates: Use ICH Common Technical Document (CTD) where applicable
• Translation Requirements: Local language IFUs and labels must be included
• Change Management: Consistent versioning and update logs across regions

Role of Parallel Scientific Advice and International Forums

To enable alignment, regulators offer collaborative programs:

• FDA–EMA Parallel Scientific Advice (PSA): For early joint feedback
• ICMRA (International Coalition of Medicines Regulatory Authorities): Discusses mutual recognition frameworks
• ICH M11 and IVD Working Group: Working on harmonized submission structures
• FDA–PMDA CDx Consultations: Joint workshops for oncology indications

Such initiatives help developers align data requirements and streamline timelines across markets.

Case Study: CDx Co-Submission for NSCLC Therapy

In a real-world example, a pharma company submitted a PD-L1 IHC assay as CDx alongside an immunotherapy drug:

• FDA: PMA submitted alongside BLA; simultaneous approval achieved
• EMA: Separate Notified Body consultation; CE marking delayed by 5 months
• PMDA: Bridging study conducted on 100 Japanese patients to supplement US data

Takeaway: Aligning trial data and preparing region-specific dossier addenda is key to success.

Co-Labeling Practices: Regulatory Expectations

Global agencies require reciprocal labeling between the drug and CDx. Best practices include:

• Drug SmPC/PI must specify biomarker detection method and associated CDx brand
• CDx IFU must state the therapeutic products it supports
• Version control and update logs to be maintained in master regulatory files

Failure to harmonize labels may trigger post-approval audits or labeling variations in certain countries.

Submission Timing Considerations

Harmonized launch is only possible if submission timelines are tightly managed:

• Begin regulatory discussions 18–24 months prior to planned launch
• Engage with Notified Bodies early under EU IVDR Article 48(3)
• Use Type C (FDA), PSA (EMA), and PMDA pre-consultation to de-risk gaps

Delays in CDx regulatory readiness can delay drug approval, especially in oncology and rare diseases.

Comparative Co-Submission Readiness Matrix

Conclusion

Global co-submission of companion diagnostics and their corresponding drugs is an increasingly critical strategy in the era of precision medicine. Regulatory agencies are moving towards harmonization, but sponsors must still navigate regional complexities, bridging studies, and documentation formats. Success requires early alignment, synchronized clinical development, and regulatory engagement through scientific advice mechanisms. The future lies in structured, global dossiers and cooperative review models, paving the way for timely patient access to personalized therapies.